01
Histamine intolerance
Bloating, migraines, flushing, and brain fog after meals — driven by inadequate DAO activity in the gut.
A patented bi-enzymatic platform pairing vegetal DAO with Catalase to degrade excess histamine down in the gut — not block it at the receptor. A root-cause approach for the next generation of antihistamine therapeutics.
Bloating, migraines, flushing, and brain fog after meals — driven by inadequate DAO activity in the gut.
Recurring hives and mast cell activation flares that classical H1 blockers cannot resolve at the source.
Histamine-mediated visceral hypersensitivity that overlaps with — and complicates — irritable bowel syndrome.
Sedation, dry mouth, and dependence — symptoms persist because root histamine load is never reduced.
Vegetal DAO (vDAO) oxidizes histamine into imidazole acetaldehyde. Catalase, working in tandem, neutralizes the resulting hydrogen peroxide — leaving no inflammatory residue. The pathway runs naturally in healthy intestines; we restore it.
Sustainable extraction procedure from legume seedlings — no animal-derived enzymes.
Pairing with catalase prevents H₂O₂ accumulation during oxidative deamination.
Proprietary matrix preserves enzyme activity through the gastric environment.
Targeted release at jejunum-ileum-colon where histamine accumulates.
Inert breakdown products excreted naturally — no receptor antagonism, no rebound.
Territory-based and indication-based licensing of our enzymatic platform — for pharmaceutical and nutraceutical companies bringing finished products to market.
Custom enzyme stabilization, dosage form engineering, and excipient compatibility studies for partners building new product lines.
Joint pre-clinical and clinical programs with universities, hospitals, and research institutions — including co-authored publication rights.
Regulatory strategy, mechanism-of-action documentation, and dossier support for partners advancing toward filings in EU, US, and APAC markets.
Ready to partner? Get in touch.
Canada (Operating Globally)
We are currently selecting partners for our licensing window. All conversations begin under NDA.
We are currently selecting partners for our 2026 licensing window. Conversations begin under NDA.